Sana Biotechnology prices $75 million public offering at $3.35 per share

Sana Biotechnology Inc. (NASDAQ: SANA) priced an underwritten public offering of 20,895,522 shares of common stock at $3.35 per share, the company announced. The biotechnology company also offered pre-funded warrants to purchase 1,492,537 shares at $3.3499 per warrant to certain investors.

The offering is expected to generate approximately $75 million in gross proceeds before deducting underwriting fees and other expenses. Sana granted underwriters a 30-day option to purchase up to 3,358,208 additional shares.

The transaction is scheduled to close on or about August 8, 2025, subject to customary closing conditions. Morgan Stanley, Goldman Sachs & Co. LLC, BofA Securities, and TD Cowen serve as joint book-running managers.

Seattle-based Sana Biotechnology focuses on developing engineered cells as medical treatments. The company operates facilities in Seattle, Washington, Cambridge, Massachusetts, and South San Francisco, California.

The offering is conducted under a previously filed and effective Registration Statement on Form S-3 with the Securities and Exchange Commission.

You May Also Be Interested In

• Sysco closes C$1.5 billion senior notes offering for Jetro acquisition
• Leader's Advantage Acquisition Corp. closes $150M IPO on Nasdaq
• Oura IPO said to draw four times demand as orders near close